SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Academia-industry partnership to promote indigenous technology commercialization in biotech sector
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The private funding rose 38% amid growing international collaborations and CDMO demand
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
